BIOTIME INC Business Operations Contracts & Agreements
11 Contracts & Agreements
- Development Agreements (4 contracts)
- Indemnification Agreements (1)
- Sales Agreements (2)
- Settlement Agreements (1)
- Supply Agreements (2)
- Termination Agreements (1)
- Sales Agreement, dated March 22, 2024, by and between Lineage Cell Therapeutics, Inc. and B. Riley Securities, Inc (Filed With SEC on March 22, 2024)
- Stipulation and Agreement of Compromise and Settlement dated October 26, 2022 (Filed With SEC on March 9, 2023)
- Form of Indemnification Agreement for directors and executive officers of the registrant (Filed With SEC on August 11, 2022)
- Second Side Letter Agreement dated December 17, 2021 between Hadasit Medical Research Services and Development Ltd. and Cell Cure Neurosciences Ltd (Filed With SEC on March 10, 2022)
- Side Letter Agreement dated December 17, 2021 between Hadasit Medical Research Services and Development Ltd., Cell Cure Neurosciences Ltd., Genentech, Inc. and F. Hoffmann-La... (Filed With SEC on March 10, 2022)
- Employment Termination and Release Agreement, dated November 18, 2015, between BioTime, Inc. and Robert W. Peabody (Filed With SEC on November 24, 2015)
- Research & Development Agreement, dated September 29, 2015, between OrthoCyte Corporation and Heraeus Medical GmbH (Portions of this exhibit have been omitted pursuant to a... (Filed With SEC on November 9, 2015)
- Amendment No. 1 to Controlled Equity OfferingSM Sales Agreement, dated March 26, 2014, between BioTime, Inc. and Cantor Fitzgerald & Co (Filed With SEC on March 26, 2014)
- Co-Exclusive Supply Agreement, dated December 8, 2010, between BioTime Asia Limited and Shanghai Genext Medical Technology Co. Ltd (Filed With SEC on March 15, 2011)
- Additional Research Agreement, dated October 7, 2010, between Hadasit Medical Research Services and Development Ltd. and Cell Cure Neurosciences Ltd (Filed With SEC on March 15, 2011)
- CO-EXCLUSIVE OEM SUPPLY AGREEMENT (Filed With SEC on August 14, 2009)
